Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2008 by Illinois Retina Associates.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Alcon Laboratories
Information provided by:
Illinois Retina Associates
ClinicalTrials.gov Identifier:
NCT00690313
First received: May 30, 2008
Last updated: June 3, 2008
Last verified: May 2008
  Purpose

Antibiotic eye drops are being used before and after intravitreal injections. Currently there is no study indicating the benefit of there usage or their dosage.

In this study we compare the efficacy of Vigamox eye drops (antibiotic)starting 3 days prior to the injection versus 1 day prior to intravitreal injection.


Condition Intervention Phase
Intravitreal Injection Patients
Drug: Vigamox
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: To Compare the Efficacy of Topical Vigamox Eye Drops at Tid 3 Days Prior to Intravitreal Injection Versus Tid 1 Day Prior to Intravitreal Injection

Resource links provided by NLM:


Further study details as provided by Illinois Retina Associates:

Primary Outcome Measures:
  • Timed study [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: July 2008
Estimated Study Completion Date: September 2009
Estimated Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm 1
Arm 1: receives Vigamox eye drops 3Xday for 3 days prior to intravitreal injection
Drug: Vigamox
eye drops 3 times day either 1 or 3 days prior to intravitreal injection
Active Comparator: Arm 2
Arm 2: receives Vigamox eye drops 3Xday for 1 day prior to intravitreal injection
Drug: Vigamox
eye drops 3 times day either 1 or 3 days prior to intravitreal injection

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient who need intravitreal injections patients who are willing to participate in the study

Exclusion Criteria:

  • Patients who are allergic to Vigamox or who have taken any eye drops within the past 3 weeks
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00690313

Contacts
Contact: Kourous A Rezaei, MD 708-596-8710 karezaei@yahoo.com
Contact: David J Baczewski 708-915-6808 davidb@illinoisretina.com

Locations
United States, Illinois
Illinois Retina Associates Not yet recruiting
Harvey, Illinois, United States, 60426
Contact: David J Baczewski    708-915-6808    davidb@illinoisretina.com   
Principal Investigator: Kourous A Rezaei, MD         
Sponsors and Collaborators
Illinois Retina Associates
Alcon Laboratories
Investigators
Principal Investigator: Kourous A Rezaei, MD Illinois Retina Associates SC
  More Information

No publications provided

Responsible Party: Kourous Rezaei MD, Illinois Retina Associates SC
ClinicalTrials.gov Identifier: NCT00690313     History of Changes
Other Study ID Numbers: Vig508
Study First Received: May 30, 2008
Last Updated: June 3, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Illinois Retina Associates:
Vigamox, topical antibiotics, Intravitreal injections, macular degeneration, endophthalmitis

Additional relevant MeSH terms:
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Ophthalmic Solutions
Tetrahydrozoline
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Autonomic Agents
Cardiovascular Agents
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Combined
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nasal Decongestants
Peripheral Nervous System Agents
Pharmaceutical Solutions
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Respiratory System Agents
Sympathomimetics
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Vasoconstrictor Agents

ClinicalTrials.gov processed this record on October 23, 2014